Drug Trial Radar · NCT02239120
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,390
Actual
Start
Nov 27, 2014
Primary completion
Aug 14, 2018
Study completion Aug 14, 2018
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 12, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 150 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).
Conditions
- Stroke
- Secondary Prevention
Interventions
optional ASA as comedicationDrug
optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
placebo to ASADrug
placebo to comparator drug
placebo to optional ASA as comedicationDrug
optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
placebo to dabigatran etexilateDrug
placebo
ASA 100 mgDrug
active comparator drug
dabigatran etexilateDrug
active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjudicated Recurrent StrokeTime frame: From randomisation until full follow up period, approximately 43 months.
- First Major Bleed (Adjudicated)Time frame: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
Locations
569 sites in 42 countries. Site status is shown where the registry gives one.
Bronislava Shafran, MD PC
Phoenix, Arizona
Westside Medical Associates of Los Angeles
Beverly Hills, California
TriWest Research Associates, LLC
El Cajon, California
University of California
Fresno, California
Glendale Adventist Medical Center
Glendale, California
Collaborative Neuroscience Network, LLC (CNS)
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
Huntington Hospital
Pasadena, California
University of California
San Diego, California
University of California
San Francisco, California
University of Colorado Denver
Aurora, Colorado
Colorado Neurological Institute
Englewood, Colorado
University of Colorado Denver
Fort Collins, Colorado
St. Mary's Hospital and Regional Medical Center
Grand Junction, Colorado
Hartford Hospital
Hartford, Connecticut
JEM Research Institute
Atlantis, Florida
Boca Raton Regional Hospital
Boca Raton, Florida
Tenet Florida Physician Services
Boynton Beach, Florida
Nova Clinical Research, LLC
Bradenton, Florida
Broward Health North
Deerfield Beach, Florida
Center for Advanced Research Excellence
Hialeah, Florida
Bruce W. Carter, Miami VA Healthcare System
Miami, Florida
University of Miami
Miami, Florida
Bay Neurological Institute
Panama City, Florida
Carol L Pappas, MD PhD PA
St. Petersburg, Florida
University of South Florida
Tampa, Florida
Vero Beach Neurology and Research Institute
Vero Beach, Florida
Palm Beach Neuroscience Institute
West Palm Beach, Florida
Augusta University
Augusta, Georgia
WellStar Medical Group - Neurosurgery
Marietta, Georgia
The Queen's Medical Center
Honolulu, Hawaii
Saint Alphonsus Medical Center-Neurology
Boise, Idaho
Northwest Heart Clinical Research, LLC
Arlington Heights, Illinois
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Medicoricium, LLC
Fairview Heights, Illinois
OSF Saint Francis Medical Center
Peoria, Illinois
Quincy Physicians and Surgeons Clinic, S.C.
Quincy, Illinois
Showing 40 of 569 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.